FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packagehl7.fhir.us.smp
Resource TypeDetectedIssue
IdDetectedIssue-betsysmith-johnson01-di01-Drug-druginteraction0.json
FHIR VersionR4

Resources that use this resource

No resources found

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

Generated Narrative: DetectedIssue betsysmith-johnson01-di01-Drug-druginteraction0

version: 1; Last updated: 2026-01-07 10:51:49+0000;

Information Source: #fIOfmNQFLI3AB7nY

Profile: Standardized Medication Profile - Medication Action Plan Detected Issue

status: Preliminary

code: Drug Interaction Alert

severity: High

patient: Smith-Johnson, Betsy Female, DoB: 1950-11-15 ( http://hl7.org/fhir/sid/us-medicare#United States Medicare Number#1PA3D58WH16)

identified: 2026-01-07 10:51:49+0000

author: Practitioner Kevin James

implicated:

detail: Selective serotonin reuptake inhibitors (eg, Sertraline HCl Oral Tablet 25 MG) may enhance the antiplatelet effect and increase the bleeding risk of purinergic signaling receptor Y12 (P2Y12) inhibitors such as Clopidogrel Bisulfate Oral Tablet 75 MG

Mitigations

-ActionDateAuthor
*drug drug interaction, change medicine dose2026-01-07 10:51:49+0000Practitioner Kevin James

Source1

{
  "resourceType": "DetectedIssue",
  "id": "betsysmith-johnson01-di01-Drug-druginteraction0",
  "meta": {
    "versionId": "1",
    "lastUpdated": "2026-01-07T10:51:49.9947894+00:00",
    "source": "#fIOfmNQFLI3AB7nY",
    "profile": [
      "http://hl7.org/fhir/us/smp/StructureDefinition/smp-medication-action-plan-detected-issue"
    ]
  },
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "status": "preliminary",
  "code": {
    "coding": [
      {
        "system": "http://terminology.hl7.org/CodeSystem/v3-ActCode",
        "code": "DRG",
        "display": "Drug Interaction Alert"
      }
    ]
  },
  "severity": "high",
  "patient": {
    "reference": "Patient/patient-betsysmith-johnson01"
  },
  "identifiedDateTime": "2026-01-07T10:51:49.9953967+00:00",
  "author": {
    "reference": "Practitioner/Practitioner-KevinJames"
  },
  "implicated": [
    {
      "reference": "MedicationStatement/bsj1-smp-medstmt-clopidogrel-1-11",
      "display": "Clopidogrel Bisulfate Oral Tablet 75 MG (Clopidogrel Bisulfate)"
    },
    {
      "reference": "MedicationStatement/bsj1-smp-medstmt-sertraline-1-8",
      "display": "Sertraline HCl Oral Tablet 25 MG (Sertraline HCl)"
    }
  ],
  "detail": "Selective serotonin reuptake inhibitors (eg, Sertraline HCl Oral Tablet 25 MG) may enhance the antiplatelet effect and increase the bleeding risk of purinergic signaling receptor Y12 (P2Y12) inhibitors such as Clopidogrel Bisulfate Oral Tablet 75 MG",
  "mitigation": [
    {
      "action": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/v3-ActCode",
            "code": "13",
            "display": "Stopped Concurrent Therapy"
          }
        ],
        "text": "drug drug interaction, change medicine dose"
      },
      "date": "2026-01-07T10:51:49.9959238+00:00",
      "author": {
        "reference": "Practitioner/Practitioner-KevinJames"
      }
    }
  ]
}